I serve as Senior Vice President, Global Head, Oncology Franchise helping to oversee the global strategy and execution of our Oncology portfolio along with our work to transform cancer care in partnership with health systems globally. In this role, I have the incredible opportunity to work alongside leaders driving our Oncology ambition across the globe. I also have the utmost privilege to see the delivery and the impact of our medicines and the challenges and opportunities that the health systems face to help improve patient care.
My deep passion for oncology comes from serving patients for nearly 15 years as a Medical Oncologist, focusing on breast and lung cancer. I am recognised internationally for my research and educational leadership, which included being principal investigator for many pivotal advances in breast cancer including several practice-changing Phase III trials.
I joined Astra Zeneca in 2019 so that I could impact more patients globally, and my initial role was to lead our global research and development in breast cancer and set the strategy to help us truly transform breast cancer outcomes. As part of that work, I led the development and execution of our breast cancer strategy, establishing the tumour council model, and designed and established our industry leading clinical development program in Breast Cancer. It has been very rewarding to see the impact of this work that has now led to the approval of transformative medicines including Enhertu.
I went on to lead the Medical organisation for our Oncology Business Unit, helping to drive our vision to redefine cancer care. Together, we advanced cancer care through robust evidence generation, scientific partnerships and helping to reimagine the future cancer care paradigm. Our science-focused and evidence-based approach has advanced our portfolio and supporting the impact of our medicines across many cancer types. I am also proud of the growth of this organization and the leaders that have joined us with shared patient-centric values.
During my career I have led and created numerous innovative educational projects in oncology and won several teaching and mentoring awards. I take pride in having mentored more than 100 residents, fellows and faculty and it truly is a great honour to see many of them develop to become leaders in Cancer centres around the globe. This focus on developing future leaders continues to be a key pillar of my leadership values.
Throughout my career I have been driven to make changes that bring meaningful benefits for people with cancer. We are at an unprecedented time where the cancer care landscape is on the verge of being completely transformed and I believe the team here at AstraZeneca has a critical role in shaping our vision and working with the oncology community to makes it a reality. Our transformative ambition is driven by a truly science and patient-focused approach to bring a range of impactful novel options for patients with varied cancer types and across different settings.
Top 25 Young Breast Oncologists in the World (2006)
Outstanding Teaching Award (2005, 2007, 2011)
Distinguished Alumni Award
CURRENT ROLE
2021-2024
2019-2021
2015-2019
Featured publications:
Work published in more than 125 peer-reviewed manuscripts including in the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology and Cancer.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H. N Engl J Med. 2018 Nov 15;379(20):1926-36.
http://www.nejm.org/doi/full/10.1056/NEJMoa1810527
Palbociclib plus endocrine therapy in older women with HR+/HER2–advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W. Iyer S, Schnell P, Bartlett CH, Johnston S. Eur J Cancer. 2018 Sep 1;101:123-33.
http://www.ejcancer.com/article/S0959-8049(18)30908-0/fulltext
Health-related quality of life of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. Breast Cancer Res Treat. 2018 Aug1;170(3):535-45.
http://link.springer.com/article/10.1007%2Fs10549-018-4769-z
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Lancet Oncol. 2017 Jun;18(6):732–742.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30312-1/fulltext
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Verma S, Bartlett CH, Schnell P, Demichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thielse A, Turner NC, Rugo HS. Oncologist. 2016 Oct;21(10):1165-75.
http://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2016-0097
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group, N Engl J Med. 2012 Nov 8;367(19):1783-91.
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey
Verma S, Provencher L, Dent R, Curr Oncol. 2011 Aug 03;18(4):180-90.
http://current-oncology.com/index.php/oncology/article/view/913
Patient adherence to aromatase inhibitor treatment in the adjuvant setting
Verma S, Madarnas Y, Sehdev S, Martin G, Bajcar J. Curr Oncol. 2011 May;18 Suppl 1:S3-9.
http://current-oncology.com/index.php/oncology/article/view/899
Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
Verma S, Ewer MS. Ann Oncol. 2011 May;22(5):1011-8.
http://www.annalsofoncology.org/article/S0923-7534(19)38535-7/fulltext
Veeva ID: Z4-70554
Date of preparation: November 2024